Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma (MM)

被引：0

作者：

Jagannath, Sundar ^{[1
]}

Vij, Ravi ^{[2
]}

Stewart, A. Keith ^{[3
]}

Somlo, George ^{[4
]}

Jakubowiak, Andrzej ^{[5
]}

Reiman, Tony ^{[6
]}

Trudel, Suzanne ^{[7
]}

Taylor, Jessica ^{[8
]}

Fuhrman, Diana ^{[8
]}

Cruickshank, Scott ^{[8
]}

Schwartz, Richard ^{[8
]}

Kunkel, Lori ^{[8
]}

Siegel, David ^{[9
]}

机构：

[1] St Vincents Comp Canc Ctr, New York, NY USA

[2] Washington Univ, Sch Med, St Louis, MO USA

[3] Mayo Clin, Scottsdale, AZ USA

[4] City Hope Natl Med Ctr, Duarte, CA 91010 USA

[5] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[6] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada

[7] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[8] Proteolix Inc, Clin Operat, San Francisco, CA USA

[9] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[10] MMRC, Norwalk, CT USA

来源：

BLOOD | 2008年 / 112卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：319 / 319

页数：1

共 50 条

[1] Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM)
Vu, Ravi
Wang, Michael
Orlowski, Robert
Stewart, A. Keith
Jagannath, Sundar
Kukreti, Vishal
Taylor, Jessica
Fuhrman, Diana
Cruickshank, Scott
Schwartz, Richard
Kunkel, Lori
Siegel, David
BLOOD, 2008, 112 (11) : 320 - 320
[2] Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM)
Jagannath, S.
Vij, R.
Stewart, K.
Somlo, G.
Jakubowiak, A.
Trudel, S.
Schwartz, R.
Siegel, D.
Kunkel, L.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[3] Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)
Samuel, David
Martin, Thomas
Wang, Michael
Vij, Ravi
Jakubowiak, Andrzej J.
Jagannath, Sundar
Lonial, Sagar
Kukreti, Vishal
Bahlis, Nizar J.
Alsina, Melissa
Chanan-Khan, Asher A.
Somlo, George
Buadi, Francis
Reu, Frederic J.
Zonder, Jeffrey A.
Song, Kevin
Stadtmauer, Edward
Wong, Alvin F.
Vallone, Marcy
Chang, Yu-Lin
Kauffman, Michael
Orlowski, Robert Z.
Stewart, A. Keith
Singhal, Seema B.
BLOOD, 2010, 116 (21) : 433 - 433
[4] Phase II Study of Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (PX-171-003)
Jagannath, S.
Vij, R.
Stewart, A. K.
Somlo, G.
Jakubowiak, A.
Reiman, T.
Trudel, S.
Taylor, J.
Fuhrman, D.
Cruickshank, S.
Schwartz, R.
Kunkel, L.
Siegel, D.
CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S61 - S61
[5] Results of PX-171-003-A0, part 1 of an open-label, single-arm, phase 2 study of carfilzomib in patients with relapsed and refractory multiple myeloma
Siegel, D.
Vij, R.
Stewart, K.
Somlo, G.
Jakubowiak, A.
Kukreti, V.
Bahlis, N.
Singhal, S.
Wong, A.
Jagannath, S.
EJC SUPPLEMENTS, 2009, 7 (02): : 571 - 571
[6] An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma
Jagannath, Sundar
Vij, Ravi
Stewart, A. Keith
Trudel, Suzanne
Jakubowiak, Andrzej J.
Reiman, Tony
Somlo, George
Bahlis, Nizar
Lonial, Sagar
Kunkel, Lori A.
Wong, Alvin
Orlowski, Robert Z.
Siegel, David S.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (05) : 310 - 318
[7] PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis
Siegel, D. S. D.
Martin, T.
Wang, M.
Vij, R.
Lonial, S.
Kukreti, V.
Bahlis, N. J.
Alsina, M.
Somlo, G.
Buadi, F.
Reu, F. J.
Song, K. W.
Kunkel, L. A.
Wong, A.
Vallone, M.
Orlowski, R. Z.
Stewart, A. K.
Singhal, S.
Jagannath, S.
Jakubowiak, A. J.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[8] A single-arm, open-label, multicenter phase I/II study of the combination of panobinostat (pan) and carfilzomib (cfz) in patients (pts) with relapsed/refractory multiple myeloma (RR MM).
Berdeja, Jesus G.
Mace, Joseph
Lamar, Ruth E.
Gian, Victor
Murphy, Patrick Brian
Patel, Manish R.
Hart, Lowell L.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[9] Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM) (PX-171-004)
Vij, R.
Wang, M.
Orlowski, R.
Stewart, A. K.
Jagannath, S.
Kukreti, V.
Taylor, J.
Fuhrman, D.
Cruickshank, S.
Schwartz, R.
Kunkel, L.
Siegel, D.
CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S78 - S78
[10] Updated Results of Bortezomib-Naive Patients in PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM)
Wang, Luhua
Siege, David
Kaufman, Jonathan L.
Stewart, A. Keith
Jakubowiak, Andrzej J.
Alsina, Melissa
Kukreti, Vishal
Bahlis, Nizar J.
McDonagh, Kevin T.
Belch, Andrew
Sebag, Michael
Gabrail, Nashat
Le, Mai H.
Bennett, Mark K.
Kunkel, Lori
Kauffman, Michael
Orlowski, Robert Z.
Vij, Ravi
BLOOD, 2009, 114 (22) : 127 - 128

← 1 2 3 4 5 →